Peptide Health Lab

Metabolic & GLP-1

Tirzepatide

Also known as: Dual GIP/GLP-1 receptor agonist, Mounjaro, Zepbound

Regulatory status
FDA approved
Evidence grade
Human RCT evidence

Last reviewed August 2, 2026 · 18 sources

What tirzepatide is and how it works

Tirzepatide is a single engineered peptide that activates two receptors at once: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both GIP and GLP-1 are incretins, gut hormones released after eating that amplify insulin secretion in a glucose-dependent way. Combining agonism at both is what distinguishes this molecule from the selective GLP-1 analogues that preceded it.[2]

The practical consequences are the familiar incretin effects, magnified: glucose-dependent insulin release, suppressed glucagon, slowed gastric emptying, and reduced appetite. What GIP agonism specifically contributes to the weight effect is still debated in the literature. A review of the class describes tirzepatide as the exemplar of a wave of multi-receptor molecules whose individual receptor contributions are being worked out after the clinical results rather than before them.[8] It is worth being precise about that: the clinical effect is well characterized; the mechanistic attribution between the two receptors is not settled.

It is given as a once-weekly subcutaneous injection of a ready-to-use solution, requires a prescription, and requires clinician-managed escalation. Unlike most compounds in this library, it has an approved manufacturer, a label, an indication, and a monitored post-marketing safety programme behind it.

What the research actually shows

The evidence base is unusually deep for a molecule this new: two large named phase 3 programmes (SURPASS in type 2 diabetes, SURMOUNT in obesity), plus dedicated trials in sleep apnea, heart failure, and liver disease.

Weight. SURMOUNT-1 randomized 2,539 adults with obesity and without diabetes across 72 weeks. Mean weight change was −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg, versus −3.1% on placebo. In the 15 mg group, 57% lost at least a fifth of their body weight.[4] The parallel trial in people who also had type 2 diabetes reports the smaller effect that population reliably shows.[5]

Direct comparison. Two head-to-head trials, both open-label, place tirzepatide ahead of a selective GLP-1 comparator: greater glycated hemoglobin reduction and greater weight loss than semaglutide 1 mg in type 2 diabetes,[2] and −20.2% versus −13.7% weight change against semaglutide at maximum tolerated dose in obesity without diabetes.[14] Comparative trials against an active drug are rare and valuable; their open-label design is the limitation to hold alongside the result.

Beyond weight. In moderate-to-severe obstructive sleep apnea, apnea-hypopnea index fell by 25.3 and 29.3 events per hour in two parallel trials, against roughly 5 on placebo.[10] In obesity-related heart failure with preserved ejection fraction, SUMMIT reported fewer composite events of cardiovascular death or worsening heart failure and better symptom scores.[12] In biopsy-confirmed steatohepatitis with fibrosis, a phase 2 trial reported MASH resolution in 44–62% of participants versus 10% on placebo.[9]

Glycemia. SURPASS-1 established the monotherapy effect: glycated hemoglobin fell 1.87–2.07 percentage points versus a slight rise on placebo, without excess hypoglycemia.[3]

Where the evidence is weak

The cardiovascular outcome evidence is noninferiority, not superiority. SURPASS-CVOT randomized 13,299 patients against dulaglutide, an active comparator rather than placebo. Tirzepatide met noninferiority (hazard ratio 0.92) but did not reach the superiority threshold.[15] There is no placebo-controlled cardiovascular outcome trial for this molecule, which means the confident outcome claims that circulate about the incretin class do not transfer to it one-for-one.

Stopping reverses it. SURMOUNT-4 was purpose-built to measure withdrawal: after a 36-week lead-in, participants switched to placebo gained 14.0% by week 88 while those who continued lost a further 5.5%.[7] Whatever this drug is, it is not a course of treatment with a defined end point in the published record.

Lean mass is the open question the headline numbers make bigger. The proportion of weight lost as lean mass varies widely across incretin studies, and no trial has tested strength or physical function as a primary endpoint.[11] Producing the largest weight reductions in the class raises the stakes on an unanswered question rather than settling it.

The safety record is shorter than the trial count implies. A meta-analysis found a significant increase in the composite of gallbladder or biliary disease and no significant pancreatitis signal, but it drew on nine trials, a modest base for rare events.[6] The rodent thyroid C-cell finding that underlies the class contraindication remains unresolved for humans by the authors' own statement.[1] Procedural aspiration risk from delayed gastric emptying is an active area with retrospective and meta-analytic evidence only.[13]

Duration. The longest trials run to about two years. Obesity and type 2 diabetes are decade-scale conditions, and nothing in the published record speaks to a decade of continuous exposure.

Reproductive-age women are the population the trials studied least and the label says most about. Pregnant participants were not enrolled in the randomized programme, so the human evidence is entirely inadvertent exposures and observational cohorts assembled afterward. That record is reassuring so far in adjusted analyses, and explicitly limited on continued use through gestation and on lactation.[18] At the same time, this is the one molecule in the class with a documented reduction in oral hormonal contraceptive exposure, attributed to a gastric-emptying delay the selective GLP-1 agonists do not produce to the same degree.[16] The gap between "least studied" and "most consequential" is unusually wide here.

Legal and regulatory status

Tirzepatide is an FDA-approved drug, marketed under separate brand presentations for its diabetes and its obesity indications. Scoped to the populations each one covers, the current US labeling carries:

  • Glycemic control in type 2 diabetes. The original 2022 approval, as an adjunct to diet and exercise, in adults and in pediatric patients aged 10 and older.[3]
  • Chronic weight management. In adults with obesity, or with overweight plus at least one weight-related comorbid condition.[4]
  • Moderate to severe obstructive sleep apnea in adults with obesity. Added in December 2024 on the strength of the SURMOUNT-OSA trials, and the first drug approved for obstructive sleep apnea at all.[10]

Note what is not on that list. The heart-failure and steatohepatitis results this page reports are trial findings, not approved indications, and the cardiovascular outcome trial established noninferiority against an active comparator rather than an indication of its own.[12][15] Each approval also belongs to the population its trial enrolled. The sleep-apnea indication is scoped to adults who have obesity, not to obstructive sleep apnea generally.

As with any approved drug, all of that means a label, an approved manufacturer, defined indications, and post-marketing surveillance.[8]

It is prescription-only, and the escalation schedule, monitoring, and stopping decisions sit with a licensed prescriber. That is a clinical fact about the molecule's regulatory status; this page takes no position on anything outside that channel, does not sell peptides, and does not tell anyone where to obtain anything.

Two details matter for readers comparing this page to the research-only pages in this library. First, approval is indication-specific: the trials supporting weight-management approval enrolled participants meeting defined body-mass-index and comorbidity criteria, and use outside those criteria is off-label practice rather than approved use. Second, tirzepatide carries the class contraindication in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, descending from the rodent C-cell literature.[1] Athletes in tested sport should check the current year's prohibited list rather than any static page.

Questions to bring to a provider

  • What is the actual target (glycemic control, weight, sleep apnea, heart failure symptoms, liver disease), and which trial population is the closest match?[10]
  • Given that SURPASS-CVOT showed noninferiority rather than superiority against an active comparator, how should cardiovascular expectations be framed?[15]
  • What is the long-term plan, given what SURMOUNT-4 showed about withdrawal?[7]
  • Is there a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2?[1]
  • Is there a history of pancreatitis, gallstones, gastroparesis, or severe reflux?[6]
  • Is an oral hormonal contraceptive in use, and what is the plan for the four-week windows after starting and after every escalation that the labeling addresses?[16]
  • Is pregnancy possible, planned, or current, and is breastfeeding in the picture?[18]
  • What should happen before any procedure requiring sedation, given the retained gastric content findings?[13]
  • How will protein intake, resistance training, and lean mass be tracked while weight is falling this fast?[11]
  • What happens at each escalation step if gastrointestinal effects become intolerable, and is stepping back down an option?[4]

The size of the effect is what makes the unanswered questions worth asking, not what makes them unnecessary.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Weight reduction in adults with obesity and no diabetes
Human RCT evidence human RCT

SURMOUNT-1 randomized 2,539 adults for 72 weeks. Mean weight change was −15.0%, −19.5%, and −20.9% on 5, 10, and 15 mg weekly versus −3.1% on placebo; 57% of the 15 mg group lost at least 20% of body weight versus 3% on placebo.

[4]

Weight reduction in adults who also have type 2 diabetes
Human RCT evidence human RCT

SURMOUNT-2 tested the same question in people with type 2 diabetes, where incretin-induced weight loss is reliably smaller. It remained clinically meaningful relative to placebo, and the trial is the reason the diabetes population is quoted separately rather than folded into the headline figure.

[5]

Superiority to a selective GLP-1 comparator
Human RCT evidence human RCT

In SURPASS-2, all three tirzepatide doses were superior to semaglutide 1 mg for glycated hemoglobin reduction and produced greater weight loss. In SURMOUNT-5, tirzepatide at maximum tolerated dose produced −20.2% weight change versus −13.7% for semaglutide at maximum tolerated dose over 72 weeks. Both comparisons used the semaglutide dose available for that indication at the time of the trial.

[2] [14]

Glycemic control in type 2 diabetes
Human RCT evidence human RCT

SURPASS-1 randomized 478 people with type 2 diabetes inadequately controlled by diet and exercise; glycated hemoglobin fell by 1.87–2.07 percentage points across doses versus a 0.04-point rise on placebo, without an increase in hypoglycemia.

[3]

Cardiovascular outcomes in type 2 diabetes
Human RCT evidence human RCT

SURPASS-CVOT randomized 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease against dulaglutide, an active comparator already shown to reduce cardiovascular events. Tirzepatide was noninferior (12.2% versus 13.1% primary events, hazard ratio 0.92) but did not meet the superiority criterion. There is no placebo-controlled cardiovascular outcome trial for this molecule.

[15]

Obstructive sleep apnea in adults with obesity
Human RCT evidence human RCT

Two phase 3 trials in moderate-to-severe obstructive sleep apnea reported apnea-hypopnea index reductions of 25.3 and 29.3 events per hour versus approximately 5 events per hour on placebo at 52 weeks, alongside improvements in hypoxic burden and patient-reported sleep measures.

[10]

Heart failure with preserved ejection fraction and obesity
Human RCT evidence human RCT

SUMMIT randomized 731 patients and reported fewer composite events of cardiovascular death or worsening heart failure (9.9% versus 15.3%, hazard ratio 0.62) and better symptom scores over a median 104 weeks. Note the composite was driven by heart-failure events, not cardiovascular deaths.

[12]

Metabolic dysfunction-associated steatohepatitis with fibrosis
Human RCT evidence human RCT

A phase 2, biopsy-confirmed trial in 190 participants reported MASH resolution without worsening fibrosis in 44–62% across doses versus 10% on placebo at 52 weeks. The investigators state directly that larger and longer trials are needed.

[9]

Durability of weight reduction after treatment stops
Human RCT evidence human RCT

SURMOUNT-4 was designed as a randomized withdrawal trial. Continued treatment produced a further 5.5% reduction from week 36 to week 88, while the placebo-switch group gained 14.0%. That is a 19.4-percentage-point difference attributable to continuing versus stopping.

[7]

Muscle-mass and physical-function consequences of the weight lost
Anecdotal reports only review

Lean mass falls with fat mass across incretin therapies, with wide variation between studies, and no randomized trial has tested strength or physical function as a primary endpoint. For the compound producing the largest weight reductions in the class, this is the most consequential unanswered question in the file.

[11]

Typical protocol range in the research

  • Phase 3 obesity trial without diabetes (SURMOUNT-1), 72 weeks of once-weekly subcutaneous injection

    5 mg, 10 mg, or 15 mg once weekly, each reached through a 20-week dose-escalation period [4]

  • Phase 3 monotherapy trial in type 2 diabetes inadequately controlled by diet and exercise (SURPASS-1), 40 weeks

    5 mg, 10 mg, or 15 mg once weekly [3]

  • Head-to-head phase 3 trials against a GLP-1 comparator: SURPASS-2 in type 2 diabetes and SURMOUNT-5 in obesity without diabetes

    5, 10, or 15 mg weekly in SURPASS-2; the maximum tolerated dose of 10 or 15 mg weekly in SURMOUNT-5 [2] [14]

  • Complication-specific phase 3 trials: obstructive sleep apnea (SURMOUNT-OSA) and heart failure with preserved ejection fraction (SUMMIT)

    Maximum tolerated dose of 10 mg or 15 mg once weekly, for 52 weeks or longer [10] [12]

These are trial schedules and labeled titration schedules: a description of what published protocols and product labeling specify, not a plan for any individual. Every schedule in the programme begins below the maintenance dose and escalates over months, because gastrointestinal tolerability tracks dose escalation directly; the escalation belongs to a prescribing clinician.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation)

    The most common adverse events in every trial in the programme, occurring primarily during dose escalation. In SURPASS-2, nausea was reported in 17–22% across tirzepatide doses, diarrhea in 13–16%, and vomiting in 6–10%. · Mostly mild to moderate, but a real cause of stopping: adverse events led to discontinuation in 4.3%, 7.1%, and 6.2% of the 5 mg, 10 mg, and 15 mg groups in SURMOUNT-1 versus 2.6% on placebo. In the cardiovascular outcome trial, gastrointestinal events were more frequent with tirzepatide than with the active comparator.

    [2] [4] [15]

  • Gallbladder and biliary disease

    A meta-analysis of nine randomized trials and 9,871 participants reported a significantly increased composite of gallbladder or biliary disease versus placebo or basal insulin (relative risk 1.97). · The same analysis did not find a significant association with pancreatitis (relative risk 1.46, confidence interval crossing 1), but the authors flag the biliary signal as warranting attention. A history of gallstones or biliary disease is worth raising with a clinician beforehand.

    [6]

  • Delayed gastric emptying and retained stomach contents before procedures

    A meta-analysis of upper-endoscopy studies reported increased residual gastric content and pulmonary aspiration risk among patients on GLP-1 receptor agonists, the receptor family tirzepatide shares. · A procedural-safety flag rather than a daily side effect: retained contents raise aspiration risk under sedation. Any planned surgery, endoscopy, or sedated procedure is a reason to tell both the prescriber and the proceduralist about incretin therapy well in advance.

    [13]

  • Thyroid C-cell findings in rodents and the medullary thyroid carcinoma caution

    Observed in rats and, to a lesser degree, mice; not observed in cynomolgus monkeys at more than 60 times human exposure levels. · GLP-1 receptor agonists stimulated calcitonin release and C-cell hyperplasia in rodents, while primates showed low thyroid C-cell receptor expression and no equivalent response; the authors state the long-term consequences in the human thyroid remain unknown. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a specific reason to raise this with a clinician before considering any incretin agonist.

    [1]

  • Reduced absorption of oral hormonal contraceptives (a labeled interaction specific to tirzepatide)

    A pharmacokinetic study found statistically significant reductions in area under the concentration-time curve and maximum concentration, and a delayed time to maximum concentration, when an oral hormonal contraceptive was given with tirzepatide. A review of six trials found no comparable effect for the selective GLP-1 agonists. The interaction is attributed to tirzepatide's larger and faster-onset delay of gastric emptying, which is most pronounced after the first dose of a new strength. · The labeling addresses it directly: patients using oral hormonal contraceptives are advised to switch to a non-oral contraceptive method, or to add a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose escalation. Hormonal contraceptives that are not taken by mouth are not expected to be affected. Because a titration schedule stacks several escalations across the first months, the window this applies to is recurring rather than one-off. Anyone using an oral contraceptive should raise this with the prescriber before the first dose and again at every step up, not discover it afterward.

    [16]

  • Pregnancy, planned pregnancy, and breastfeeding

    Not studied. Pregnant participants were not enrolled in the randomized programme; the human record consists of pregnancies that occurred inadvertently during trials plus observational cohorts assembled afterward. A systematic review of 36 studies of GLP-1 and dual GLP-1/GIP receptor agonists found that periconceptional or early-pregnancy exposure was not consistently associated with increased major congenital malformations, fetal growth restriction, stillbirth, or neonatal mortality in adjusted analyses. The same review notes that data on continued use through gestation remain limited and lactation data are sparse. · In pregnant rats given tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure; in rabbits, fetal growth reductions occurred at clinically relevant exposures. The labeling states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs discontinuation when a pregnancy is recognized. Restored fertility after weight loss is itself a reason unplanned pregnancies have become more common on these drugs, which is why the oral-contraceptive interaction above and this entry are the same conversation. Pregnancy, intention to conceive, and breastfeeding all belong in the discussion with the prescriber before starting and at every review.

    [18] [17]

  • Loss of lean body mass alongside fat mass

    Reported with wide heterogeneity across incretin trials: a review describes lean-mass reductions from roughly 15% of total weight lost in some studies up to 40–60% in others. · Because tirzepatide produces the largest weight reductions in the class, the absolute lean-mass question is proportionally larger. No trial has used strength or physical function as a primary endpoint, so the functional consequence is unestablished rather than reassuring.

    [11]

  • Rapid weight regain when treatment stops

    In the SURMOUNT-4 randomized withdrawal design, participants switched to placebo after a 36-week lead-in regained weight such that they were 14.0% heavier at week 88, versus a further 5.5% reduction on continued treatment. · Not an adverse effect in the pharmacological sense, but it is the practical one: the trial design was built specifically to measure what happens on withdrawal, and the answer was substantial regain.

    [7]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Approved tirzepatide is manufactured as a ready-to-use aqueous solution in single-dose pens or vials; it is not supplied as a freeze-dried powder, so there is no lyophilized form inside the approved supply chain to store. The entire published trial programme used sponsor-supplied injection product, and no published study characterizes the stability of powdered material labeled as tirzepatide outside that chain.
Reconstituted storage
Trial and labeled product is handled as refrigerated pharmaceutical material: kept cold, protected from light, and used within the limited in-use window the product labeling assigns. The exact temperature range and in-use period for any given presentation come from the labeling dispensed with the prescription and from the prescribing clinician, not from this page.
Reconstitution
Not applicable. Approved tirzepatide is dispensed as a ready-to-use solution in a single-dose pen or vial. There is no lyophilized powder and nothing to reconstitute.
Handling notes
Being an approved drug means a manufacturer stability programme, an expiry date, and a labeled in-use period actually exist for this molecule. That is a genuine difference from the unapproved compounds elsewhere in this library, where storage guidance is convention rather than specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include Tirzepatide

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

  • Weight Loss

    A research reference for the incretin compounds mapped to weight loss, covering what the registrational trials measured, what happens when treatment stops, what the body-composition data show, and which parts of the picture come from a label rather than from a trial.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

18 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder